Results 1 to 10 of about 10,093 (182)

Roles of omalizumab in various allergic diseases

Allergology International, 2020
IgE and mast cells play a pivotal role in various allergic diseases, including asthma, allergic rhinitis, and urticaria. Treatment with omalizumab, a monoclonal anti-IgE antibody, has significantly improved control of these allergic diseases and ...
Yoshimichi Okayama, Hisako Matsumoto, Hiroshi Odajima, Shunsuke Takahagi, Michihiro Hide, Kimihiro Okubo   +5 more
doaj   +3 more sources

Omalizumab in Children [PDF]

Paediatric Drugs, 2014
Omalizumab is a recombinant humanized monoclonal antibody that reduces levels of circulating immunoglobulin E (IgE) and expression of IgE high-affinity receptors on mast cells and basophils, interrupting the subsequent allergic inflammatory cascade.
Amelia Licari, Riccardo Castagnoli, Silvia Caimmi   +2 more
exaly   +4 more sources

Prevention of omalizumab for seasonal allergic rhinoconjunctivitis: a retrospective cohort study

Frontiers in Immunology, 2022
BackgroundAllergic rhinoconjunctivitis (ARC) is an allergic disease that is characterized by conjunctival and nasal symptoms such as edema and congestion of conjunctiva, rhinorrhea, sneezing, and blocked nose.
Rui Tang, Shubin Lei, Liping Zhu, Yuzhen Lv, Hong Li   +4 more
doaj   +1 more source

Omalizumab for the treatment of chronic spontaneous urticaria: association between body mass index and outcome

Dermatology Practical & Conceptual, 2022
Introduction: Omalizumab has been recently registered as a third-line therapy for chronic spontaneous urticaria. Objectives: In this study, we aimed to provide real life data by reporting our experience with omalizumab in the treatment of chronic ...
Irene Russo, Sara Cazzolla, Francesca Pampaloni, Mauro Alaibac   +3 more
doaj   +1 more source

High‐dose non‐sedating antihistamines are used insufficiently in chronic urticaria patients treated with omalizumab

Clinical and Translational Allergy, 2021
Background The lifetime prevalence of chronic urticaria (CU) is 0.5%–1%. In some patients with CU, symptomatic control is not achieved with non‐sedating second‐generation H1 antihistamines (nsAH1) alone, even with quadrupled standard doses as recommended
Hanne Madsen, Charlotte G. Mortz, Carsten Bindslev‐Jensen, Mette Reilev, Jesper Hallas, Daniel P. Henriksen   +5 more
doaj   +1 more source

PK/PD modeling to characterize placebo and treatment effect of omalizumab for chronic spontaneous urticaria

CPT: Pharmacometrics & Systems Pharmacology, 2023
The pharmacokinetic (PK) characteristics of omalizumab and its pharmacodynamic (PD) effect in patients has yet to be fully characterized in chronic spontaneous urticaria, which could elucidate its pathogenesis and treatment response.
Elise Oh, Russ Wada, Kha Le, Yanan Zheng, Jin Jin, Victor Poon, Kit Wong, Ryan Owen, Kenta Yoshida   +8 more
doaj   +1 more source

Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma

World Allergy Organization Journal, 2022
Omalizumab is recommended as an add-on therapy in patients aged ≥6 years with inadequately controlled, moderate-to-severe persistent allergic asthma. The efficacy and safety of omalizumab treatment in allergic asthma clinical trials and its effectiveness
Nicola A. Hanania, MD, Robert Niven, MD, Pascal Chanez, MD, PhD, Deschildre Antoine, MD, PhD, Pascal Pfister, MD, Lorena Garcia Conde, MD, Xavier Jaumont, MD   +6 more
doaj   +1 more source

Omalizumab-A review

Indian Journal of Dermatology, 2015
Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE). The US FDA has approved this molecule for chronic urticaria.
Kiran Godse, Aayushi Mehta, Sharmila Patil, Manjyot Gautam, Nitin Nadkarni   +4 more
openaire   +3 more sources

Severe pediatric asthma with a poor response to omalizumab: a report of three cases and three-dimensional bronchial wall analysis

Journal of International Medical Research, 2022
Omalizumab is used for the treatment of persistent severe allergic asthma in adults and children. However, some patients remain symptomatic even after omalizumab treatment. In bronchial asthma, chronic inflammation of the bronchial wall causes thickening
Mitsuru Tsuge, Masanori Ikeda, Yoichi Kondo, Hirokazu Tsukahara   +3 more
doaj   +1 more source

Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America

World Allergy Organization Journal, 2019
Background: Updated urticaria guidelines recommend that patients should be assessed for disease activity, severity, control, and quality of life at baseline and follow up.
Ivan Cherrez-Ojeda, Marcus Maurer, Jonathan A. Bernstein, Emanuel Vanegas, Miguel Felix, German D. Ramon, Luis Felipe Ensina, José Ignacio Larco Sousa, Edgar Emilio Matos Benavides, R. Cardona Villa, P. Latour Staffeld, Blanca María Morfin-Maciel, Jose Mori, Paul Wilches C, Valeria L. Mata, Annia Cherrez   +15 more
doaj   +1 more source